Stocks To Watch Week Of Jan. 30

by: VFC's Stock House

At the conclusion of each week, We examine the stocks and stories that made news through various sectors during previous trading week, but may also make headlines or influence trends during the upcoming week as well.

This week - in honor of the upcoming Super Bowl that'll see the Giants repeat their previous big game success against the Pats - we'll focus on some of the high runners from last week, which also might be ready to make some noise during the upcoming trading week as well.

Like money placed on the Giants in San Fransisco, money placed on the following stocks could also be a good move, judging by recent events and price action ...

Siga Technologies (NASDAQ:SIGA): High trading volume fueled a ten percent run for Siga Technologies on Friday, and with increasing positive coverage from various media outlets, it could be a good time to consider that the large short position in the SIGA stock may be ready to start covering.

For the better part of the last year, SIGA has been beaten down by questionable political practices and a negative decision by a judge in relation to a lawsuit filed by rival PharmAthene (NYSEMKT:PIP), but shares are already trading well off their recent lows and many predict that there could be more in store.

A similar move took place on the previous Friday, however, but that run was essentially wiped out during the following week, but the trading action during the week was also a decent indicator that the three dollar level is new support moving forward.

The consistent late week price increases could also be an indication that some are expecting an imminent news release and either don't want to be left out or left short on Monday morning, should news materialize.

It's worth keeping an eye on this one, especially with renewed vigor behind growing media coverage.

GelTech Solutions (OTCQB:GLTC): Volume and investor interest has been slowly increasing for this stock, with another five percent increase put in the bags this past Friday. GelTech's revolutionary lead product, FireIce, could change the scope of how fires are fought globally, especially if testimonials such as those provided by firefighters in Montana keep rolling in.

With sales and distribution expected to pick up dramitically during the year, the implications of FireIce on the global market cannot be ignored, and therefore neither can we ignore the potential implications of those sales on the GLTC share price.

As noted previously, foreign governments have already began taking notice of FireIce and its revolutionary water-enhancing and firefighting properties, and designations achieved both in the US and abroad have quickly made it a global commodity.

GelTech recently secured some funding to support the upcoming distribution boom, so don't let this one slip too far from the radar. Again, take note of the comments from firefighters in Montana; as the word spreads, sales could quickly increase:

"FireIce far exceeded our expectations. The homes coated with FireIce were not damaged by the fire. Everything that we didn't touch with FireIce was nothing but ashes."

Dendreon Corporation (NASDAQ:DNDN): The Dendreon surge continued last week, with shares touching above the fifteen dollar mark at one point - making this one a quick double from where it closed 2011. This year's surge was sparked by a positive sales update for the company's prostate cancer immunotherapy treatment, Provenge, and a turnaround in media coverage has many placing renewed faith in the ability of DNDN to once again rise from the ashes.

Given the heavy short interest, it should be expected that there is still more to come with this price increase, as any continued positive news updates may compel the shorts to cover in a hurry; which, of course, could lead to a quicker squeeze.

Already a winner for 2012, the DNDN run might still have legs.

Immunocellular Therapeutics (NYSEMKT:IMUC): Already a stock to watch this year after a share price drop that resulted from a recent announcement of financing, shares of Immunocellular Therapeutics have quickly rebounded and this story continues to be one worth following.

As mentioned earlier this month, results from an ongoing Phase II trial measuring ICT-107 as an immunotherapeutic treatment for a devastatingly aggressive form of brain cancer - glioblastoma (GBM) - are due to be released within the year, and it could be anticipation of those results that led Ayer Capital Management to take a seven percent position in IMUC during the latest round of financing.

Ayer is one of the most well-known healthcare related hedge funds out there and have - or have held - positions in many of the better-known companies out there, such as Teva (NYSE:TEVA), Celgene (NASDAQ:CELG) and Oncothyreon (ONTY).

With the revelation of a new institutional holding, it's no surprise that IMUC has already moved higher by over 30% from the recent lows, and another speculative run could be in store in anticipation of the interim results that are due out within the year.

Still one to watch, for the reasons already discussed, but also because Immunocellular's next-generation technology makes the company an attractive buyout candidate, as well.

Mannkind Corporation (NASDAQ:MNKD): A solid string of increasing volume took shares of Mannkind Corporation back to over the three dollar level last week, and the huge short ratio indicates that higher prices could be in store if rapid short covering creates a squeeze.

Insiders also hold a strong percentage of company shares, creating an intriguing situation to monitor and placing MNKD on the list of potential 2012 rebound stories.

While the above-mentioned factors can contribute to a minimal - and potentially only temporary - rebound in price, it'll be the success or failure of Afrezza that dictates the long term future of this company. Afrezza is Mannkind's developmental insulin spray for diabetics and has failed twice at making it through the FDA to market.

The FDA may change it's tune, however, if the latest round of trials using Mannkind's next-generation inhaler are as successful as the previous trials that used a different inhaler.

Watch this one; still a risky bet, but the insider ownership and short interest is still intriguing enough to play.

Biovest International (OTC:BVTI): In just ten days time this stock has become a smoothe double.

Things started getting interesting again for Biovest International late last year when company officials started showing up at various conferences around the U.S., and the news flow from early this year has already supported the positive trend.

In another recent news release the company demonstrated that positive strides are being made in Europe, geared towards approval of BiovaxID as an immunotherapeutic treatment for non-Hodgkin's lymphoma, to go along with positive developments relating to an approval in the US, too.

The quick double in price this year has been supported by bigger - although not blow-away - volume than what we've seen over the past year or so, but look for the interest to grow even more, should BVTI start circulating the message boards and media outlets as another good, but speculative, cancer immunotherapy play.

It's already been a solid year for Biovest, a majority-owned subsidiary of Accentia Biopharmaceuticals (OTC:ABPI), but the momentum might only just be building if the news updates continue to paint an encouraging picture.


Netflix (NASDAQ:NFLX): The Netflix rebound continued in a huge way over the past couple of weeks, marking this company as another one whose stock price has doubled, or come close to it, during the opening months of the new year.

Questionable decision making by management last year looks to be just a speck in the rear-view mirror as the rebounding share price marks 2012 as a solid rebound year investors. Still an exciting one to watch, although other companies - such as Amazon (NASDAQ:AMZN) are sure to continue offering stiff competition to Netflix's services moving forward.

Celsius Holdings (OTCQX:CELH): The ever-modest volume of Celsius Holdings picked up a bit last week before Friday's trading slapped a big zero in the "shares traded" column, but the increased interest - however short-lived it was - returned CELH to right around where it closed on the first trading day of 2012.

With the worst possibly behind this company, a few quarters of steady sales may have 2012 primed to become a rebound year if sales of the calorie-burning Celsius beverage can grow from the two million dollars per quarter that has become the recent norm.

It's worth watching Celsius again, as the brand looks to have found a decent nich in the pre-workout beverage arena.

Titan Pharmaceuticals (NASDAQ:TTNP): Volume has been steady for shares of Titan Pharmaceuticals , but the share price has been inching downards for months and little news has made it's way from the Titan printing presses.

With Probuphine seemingly in the final phases of development before being put before the FDA, and with the ProNeura drug delivery technology holding plenty of potential as a drug delivery technology, Titan should remain on the radars of speculative biotech investors for - if nothing else - its potential as a buyout candidate.

This stock usually generates a decent run after months of a declining share price on little or no news, so as risky as a pick it may be, I usually like a reinvigorated buy sentiment at right around a buck. That said, it's also worth taking some money off the table into any significant run.

Cel-Sci Corp (NYSEMKT:CVM): Cel-Sci Corp had been on the move all month long before a financing deal derailed the run last week. The significant short term move made for a nice trading opportunity, but the long termers are looking towards interim and final results from the ongoing Phase III for the immunotherapeutic head and neck cancer treatment, Multikine.

The cash raised from last week's deal will be used to fund the continuance of the trial, for which Orient Europharma and Teva have already come on board as partners.